Revance’s leadership is committed to setting the new standard in healthcare and has deep experience commercializing products in highly competitive markets. As a group, we represent more than a century of experience launching innovative products that change people’s lives.
For customer service, product information, new accounts or adverse events call: 877-3REV-NOW
1222 Demonbreun St
20th Floor
Nashville, TN 37203
Jeff Bedard is the Chief Executive Officer of Revance. Before founding Crown Laboratories, Inc. (a Revance company) in 2000, Mr. Bedard held positions in sales and market development with Stiefel Laboratories, Inc. and Herald Pharmacal, Inc. Mr. Bedard owned a consulting firm, providing marketing and business development management advice for small to medium pharmaceutical companies.
Mr. Bedard serves on the Boards of the ETSU Foundation, Avadim Health, Tri-Cities Airport Authority, and Life Science Tennessee. He recently was inducted into the Science Hill Sports Hall of Fame.
Mr. Bedard graduated with honors from the University of Iowa with a degree in Chemistry.
Nadeem Moiz is the President, Chief Operating Officer, and Chief Financial Officer of Revance. An avowed growth business leader, Mr. Moiz is inspired by the work of Muhammad Yunus, the Bangladeshi social entrepreneur, banker, economist, civil society leader and Nobel Peace prize laureate, whom he first heard speak at Harvard Business School. Since then, Mr. Moiz has been partnering with leading private equity firms to help emerging growth companies achieve scale by encouraging entrepreneurship and sound business practices.
Mr. Moiz is recognized as a strong strategic and operational leader. Prior to joining Revance, Mr. Moiz was the COO and CFO of a home building products company, Select Interior Concepts, that he took public and listed on NASDAQ in 2018. In addition, his experience includes CFO and leadership roles in multiple billion dollar global industrial and automotive companies. He most recently served on the board of Susan G. Komen, the largest non-profit addressing breast cancer support and research, and was also on the board of the Salvation Army and advisory board of International Assist that focused on diabetes in Belize.
Mr. Moiz holds a Bachelor of Science in Accounting from the University of Florida, an MBA in finance from Florida A&M University, and Advance Management study at Harvard Business School. He is also a Certified Public Accountant and Certified Global Management Accountant. He lives in Atlanta with his wife and 2 kids, is an avid scuba diver and sailor as he grew up in the Cayman Islands.
Satish Kalala is the Chief Technology Officer of Revance.
Mr. Kalala is a seasoned global technology leader who will drive Revance’s technology transformation, modernization, and digital innovation initiatives. His recent experience includes serving as an Operating Principal at a private equity firm and as the first CTO at Select Interior Concepts (NYSE:SIC) with multiple successful exits, as well as being the Founding and Managing Partner of A5 Ventures with a rapid-growth portfolio. Previously, he co-founded and led several fast-growing startups as CEO of Vixta Solutions at Simon Group Holdings, and provided M&A advisory services at Deloitte Consulting for several mega global transactions.
Mr. Kalala earned a Bachelor of Science degree in Computer Science & Engineering from SVU College of Engineering in India, an MBA in General Management & Corporate Strategy from the University of Michigan, and executive education from Harvard Business School. Outside of work, he is a co-founder and board member of the KR Global Foundation, an advisor for startups, and an avid Michigan football fan.
Mr. Crowe serves as Revance’s Chief Accounting Officer. Prior to joining Revance, Mr. Crowe was the senior manager of the Consulting and Audit Departments at a regional accounting firm, Blackburn, Childers and Steagall, PLC. While in public practice, Mr. Crowe specialized in manufacturing clients and medical practices.
Mr. Crowe earned his Bachelor’s degree in Business Administration with concentrations in both Accounting and Logistics and Transportation from the University of Tennessee.
Thomas Hitchcock, Ph.D. serves as the Chief Innovation Officer for Revance and oversees Innovation, Clinical Development, Biological Sciences, Formulations and Research & Development for Revance and its subsidiaries. Before his role as CIO, Dr. Hitchcock served as the inaugural Chief Scientific Officer for Crown Laboratories (a Revance company). Prior to his time with Revance, he was the Founder of Xycrobe Therapeutics Inc. and served as its Chief Executive Officer until acquired by Crown in 2019. Additionally, he was the Co-founder and Chief Scientific Officer overseeing Clinical & Medical Affairs at Bellus Medical from its inception up to the acquisition by Crown Laboratories in 2018. He also currently serves as an adjunct faculty member of the East Tennessee State University Department of Biomedical Science.
Previous to his work in the industry, Dr. Hitchcock performed research at Weill Cornell Medical College, where he studied multiple myeloma genetics. He also performed post-doctoral research in tissue engineering and regenerative medicine at Duke University and Yale University. Following his post-doctoral studies, Dr. Hitchcock began working in the field of dermatology at emerging companies such as Ulthera, Inc. (acquired by Merz in 2014), as well as consultancy for companies such as Boehringer Ingelheim and Bayer.
Dr. Hitchcock has more than 15 years of research experience, including Basic Science, Proof-of-Concept, Pre-Clinical and Clinical Research across several therapeutic areas such as Cardiology, Oncology, Gene Therapy, Plastic/Facial Plastic Surgery, Dermatology and Aesthetic Medicine.
Dr. Hitchcock earned his Ph.D. in Genetics from Clemson University and completed post-doctoral trainings at Duke University and Yale University in Biomedical Engineering, Vascular Biology and Therapeutics.
Throughout his twenty-five-year career in publicly traded and privately held organizations, Dr. Argano has been responsible for leading large-scale growth and transformation. Most recently, Dr. Argano served as SVP, Chief Human Resources Officer at LL Flooring, a leading specialty retailer of hard-surface flooring. Prior to LL Flooring, he served as SVP, Chief Human Resources Officer at The Fresh Market, Inc., a nationwide specialty grocer with over 14,000 associates, and at Altar’d State, Inc., a women’s lifestyle brand.
Dr. Argano earned his Ph.D. from Tennessee Temple University in Chattanooga, TN and a Master’s degree from Beacon College in Columbus, GA. His dissertation examined the relationship between leaders’ personality traits and levels of commitment within organizations and he has lectured internationally on the topics of organizational culture and leadership.
Shellie Hammock is Executive Vice President and General Counsel of Revance.
Ms. Hammock brings extensive experience in business and corporate law to Revance. Most recently, she served as Deputy General Counsel of GCP Applied Technologies Inc. Prior to GCP, she was Deputy General Counsel at Forward Air Corporation. She began her legal career in private practice with Morris, Manning & Martin, LLP and then Carlton Fields, P.A., in Atlanta, Georgia.
Ms. Hammock received her law degree from Mercer University, Walter F. George School of Law, cum laude, and her undergraduate degree from Furman University.
Michael McKenna is a seasoned business leader with more than 25 years of commercial expertise within the medical device and pharmaceutical industries. Michael joined Bellus Medical, a Revance company, in 2017 as Vice President of Sales. He is a strategic thinker who has a strong aptitude for collaboration and engagement that generates brand adoption and customer loyalty. A proven and dedicated leader, his commitment to and belief in what he does are felt throughout his team and the entire organization, inspiring those around him to be at their best, every day.
Previously, Michael was the Vice President of North American Sales and Operations at Suneva Medical where he successfully led strong sales revenue growth over several years while directing the rapid development of Suneva’s outside sales team, customer service group, and inside sales force to support its expanding needs. Prior to that, Michael progressively accomplished 14 years at Medicis Pharmaceutical Corp. in various leadership positions where he consistently exceeded annual company sales goals during his tenure.
Michael has a Bachelor of Science Degree in Business Administration Management from Auburn University.
Mr. Gallopo joined Crown Laboratories, a Revance company, in 2019 to lead the OTC Consumer business. Mr. Gallopo brings a vision of building and reestablishing brands through product innovation and retail channel expansion. Mr. Gallopo’s experience ranges across all aspects of dermatology sales and marketing including OTC, medical device, aesthetics, and Rx. Mr. Gallopo has worked for several significant players in the space including Merz, GSK, and Stiefel. His track record includes the establishment of numerous #1 OTC and Rx brands as well as the development and execution of customer loyalty programs.
Mr. Gallopo obtained his Bachelor of Science & Business Administration degree from Villanova University.
Ms. Walker brings over 20 years of experience to Revance, having led category-defining products and portfolios across leading organizations in medical devices, medical aesthetics, surgical aesthetics, medical dermatology, and regenerative therapies. She has a proven track record of successfully building new markets, launching products, and driving innovation by leveraging both the art and science of strategic marketing programs. Previously, Ms. Walker led category-defining products at Allergan in both Medical Dermatology and Aesthetics, and held senior leadership roles in various functions at Syneron Candela, SENTÉ® Labs, DermTech, and Sientra, Inc.
Ms. Walker earned a Bachelor’s degree in Marketing from California State University, Long Beach.
Conor Gallagher, Ph.D. joined Revance in April 2018 and currently serves as Chief Scientific Officer of Revance.
Dr. Gallagher brings over 20 years of industry and academic experience primarily focused in the neurotoxin area but also holds extensive knowledge of medical device and small molecule development and post-market activity. Prior to joining Revance, he spent 12 years at Allergan in a variety of Global Medical Affairs roles of increasing seniority.
Dr. Gallagher holds a Ph.D. in Neurophysiology from the University of Toronto, a Master of Science in Anatomy from University College, Cork, and an undergraduate professional degree in Physiotherapy from University College Dublin.
Bill Meury is the Chief Executive Officer of Anthos Therapeutics and is also a member of the Board of Directors. Mr. Meury joined Anthos after leading Karuna Therapeutics, a biopharmaceutical company focused on neuroscience, until its merger with Bristol Meyers Squibb for $14B. Mr. Meury currently serves as Chairman of the Board for Revance. Mr. Meury served as the Chief Commercial Officer for Allergan from 2015-2020 where he had responsibility for over 50 products with $16B in revenue and over $3B in sales and marketing investment. He led multiple global divisions consisting of 7,500 employees, including marketing, sales, business analytics, marketing operations, managed care, pricing, and customer service. Previously, Mr. Meury served as President, Branded Pharmaceuticals for Actavis, and Executive Vice President, Sales and Marketing, Forest Laboratories, Inc.
Mr. Meury led three large commercial integrations, including the $28B merger between Forest & Actavis, the $66B merger between Actavis & Allergan, and the $63B merger between Allergan & Abbvie. Mr. Meury has over 25 years of experience in biopharmaceuticals and was directly responsible for over 20 new product launches across 10 therapeutic areas during his career. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. Mr. Meury serves on the Board of Directors for Syndax, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. He also serves on the Board of Directors for the Jed Foundation, a non-profit organization that protects emotional health and prevents suicide for teens and young adults in the United States.
Mr. Meury has a B.A. in Economics from the University of Maryland.
Jeff Bedard is the Chief Executive Officer of Revance. Before founding Crown Laboratories, Inc. (a Revance company) in 2000, Mr. Bedard held positions in sales and market development with Stiefel Laboratories, Inc. and Herald Pharmacal, Inc. Mr. Bedard owned a consulting firm, providing marketing and business development management advice for small to medium pharmaceutical companies.
Mr. Bedard serves on the Boards of the ETSU Foundation, Avadim Health, Tri-Cities Airport Authority, and Life Science Tennessee. He recently was inducted into the Science Hill Sports Hall of Fame.
Mr. Bedard graduated with honors from the University of Iowa with a degree in Chemistry.
David F. Solomon is a Partner at Hildred Capital Partners. Mr. Solomon serves on the Board of Quantum-Si, an innovative life sciences company; he is an Executive Partner at Tyree & D’Angelo, an investment firm focused on acquiring and consolidating individual operating healthcare-related businesses; and he is a member of the Shareholder’s Council for Columbia Care, the leading medical marijuana business in the U.S. Prior to Hildred, Mr. Solomon served on the Board of Directors for Moksha8, a Latin American pharmaceutical company with commercial operations in Mexico and Brazil, and on the Board of Directors of Trevena, a public clinical stage biotech company, working in the area of G protein coupled receptor targeted medicines.
Prior to launching Hildred Capital Partners, Mr. Solomon spent 14 years at Forest Laboratories, ultimately as Senior Vice President, Corporate Development & Strategic Planning. In that capacity, Mr. Solomon was responsible for Forest’s Business Development activities, including all M&A, licensing and product acquisitions. He also had responsibility for Forest’s Alliance Management group, which managed Forest’s many collaborations, and its Strategic Planning functions, which focused on the review and evaluation of novel business opportunities, as well as life-cycle planning for Forest’s portfolio. In addition, Mr. Solomon managed Forest’s business outside the United States, including its European, Canadian and Latin American operations. He was also responsible for all of the company’s Operations, including Manufacturing and Distribution, as well as its Informatics, Compliance and Quality Affairs functions. Mr. Solomon departed Forest, after the company was acquired by Actavis for approximately $28 billion in July 2014.
Prior to joining Forest, Mr. Solomon practiced entertainment law at Paul Weiss Rifkind Wharton & Garrison in New York. Following that, he worked as Director of Creative Affairs at Paramount Pictures in Los Angeles, overseeing development and production of feature films for the studio and as an independent producer with Davis Entertainment, based at 20th Century Fox. Mr. Solomon has also produced the Peabody Award winning documentary film Rebirth, about a group of people whose lives were dramatically impacted by September 11th, which premiered at the Sundance Film Festival in January 2011.
Mr. Solomon serves on the Board of Directors of Lincoln Center Theater and the Municipal Art Society and on the Executive Board of the Yale Dramat Alumni Association. Mr. Solomon has also served as a member of the Yale University Council Committee on Theater at Yale. Mr. Solomon graduated summa cum laude with a B.S. in Biology from Yale College, where he was elected to Phi Beta Kappa and received the Jonathan Edwards Fellows Prize for Academic Achievement and the Henry E. Ellsworth Prize for the most significant senior thesis in the Natural Sciences. He received his J.D. from Yale Law School, where he was a Coker Fellow and a Senior Editor of the Yale Law Journal.
Stephen Hallenbeck is a Partner at Hildred Capital Management. He previously served as the Director of Private Equity at Hildred Capital Partners, where he was responsible for sourcing, evaluating, executing and managing investment opportunities within the Hildred private equity portfolio. Since joining HCP in 2016, Mr. Hallenbeck led six majority buyout acquisitions, arranging total debt and equity financings in aggregate of $450 million. In connection with his oversight at Hildred, Mr. Hallenbeck serves on the Board of Directors for Project Natural, a leading supplier of natural therapeutic consumer healthcare products; DermCare, a dermatology practice management company; SportsMed, a physical therapy practice management company; and Crown Laboratories, a premier dermatology, aesthetic and skincare product business. In addition to his role at HCM, Mr. Hallenbeck serves on the Board of Directors and Financial Sustainability Committee of the Triangle Fund, a community and youth-focused non-profit organization based in upstate New York.
Prior to joining Hildred, Mr. Hallenbeck worked at Deutsche Bank Securities from 2009 to 2016, where he most recently worked in the Financial Sponsors Group. In this role, Mr. Hallenbeck identified and evaluated leveraged acquisitions and capital markets financings for both prospective and current portfolio companies of private equity firms. Prior to his time in the Financial Sponsors Group, Mr. Hallenbeck spent time as a member of Deutsche Bank’s Healthcare Investment Banking team, focusing on M&A, debt and equity transactions for both private and public companies within the sector.
Mr. Hallenbeck received a B.A. in Economics with honors from Vanderbilt University.
Dan Turner has 30 years of experience as an entrepreneur, operating manager and investor. He founded Montreux Equity Partners and has been a General Partner and Managing Member with Montreux since 1993.
Mr. Turner has invested in companies across consumer, healthcare services, pharmaceuticals and technology sectors. Some of his previous investments include Paymap (acquired by First Data Corp), Peapod (IPO; acquired by Royal Ahold), and Great Lakes Health Plan (acquired by United Healthcare). Mr. Turner is a member of the Board of Directors of Avantis Medical, GC Aesthetics, Moksha8, Pure Life Renal, KNOW Foods, and Crown Laboratories, Inc. He is a member of the Advisory Board of the Lester Center, located at the Haas School of Business, University of California, Berkeley.
Mr. Turner previously served as Montreux’s representative to the Board of Directors of Glaukos (NYSE: GKOS), Tobira Therapeutics, Epirus Biopharmaceuticals (NASDAQ: EPRS), Renal CarePartners (sold to Ambulatory Services of America in 2011), Cerexa (sold to Forest Laboratories in 2007), NovaCardia (sold to Merck in 2007), and Peninsula Pharmaceuticals (sold to Johnson & Johnson in 2005).
Mr. Turner started his career with Price Waterhouse in the high technology group. He later became the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals (NYSE: WPI) in 1997. Prior to founding Montreux Equity Partners, Mr. Turner was a Principal in the Turnaround Group for Berkeley International.
Mr. Turner holds a B.S. from California State University, Sacramento and attended the M.B.A. program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is a Certified Public Accountant.
Adair Newhall is a Partner at Stepstone Group and is responsible for sourcing and due diligence efforts on fund, direct and secondary opportunities. He is also actively involved in the Firm’s healthcare investment practice and Portfolio Impact Program, which is focused on maximizing Stepstones’s human and enterprise capital contributions to General Partners and portfolio companies through strategic introductions to potential customers, executive talent, corporate partners, investors, acquirers and service providers, support in fundraising and capital management, operational and strategic guidance, the evaluation of product-market fit, and more.
Adair currently serves on the Bright Health & Revance boards and sits as an observer on the boards for Aetion, Entrada, and Paladina Health. In addition, Adair advises five different Venture Advisory Boards for venture capital firms and six passive direct healthcare investments (HilleVax, Imago Biosciences, Kallyope, NGM Bio, Phathom Pharma, PowerVision, ScoutBio, and Tenaya Therapeutics). Adair previously served as a Principal at Domain Associates, a leading healthcare-focused venture capital firm and a Greenspring fund manager. At Domain Associates, Adair held board observer positions with several portfolio companies, including Applied Proteomics, Astute Medical, BioNano Genomics, CoLucid Pharmaceuticals, Otonomy, and Xagenic. Prior to joining Domain Associates in August 2009, Adair worked in the business development group at Esprit Pharma, where he assisted with multiple product acquisitions and the subsequent sale of the company to Allergan (NYSE: AGN) for $370 million. Before that, he worked at ESP Pharma, which was acquired by PDL BioPharma (NASDAQ: PDLI) for $514 million.
Adair received his MBA from the Darden Graduate School of Business Administration at the University of Virginia and his undergraduate degree from the University of Pennsylvania.
Adair is a Kauffman Fellow, a member of the Baltimore/Washington Chapter of YPO, and a co-founder of the UVa Venture Summit.
Philanthropically, he is passionate about We.Org, Living Classrooms Foundation, and Darden Business School Foundation Board of Trustees.
Wael Fayad has over 25 years of experience in the life sciences industry. He served as head of business development at Forest Laboratories Inc. and was a member of the leadership team that built Forest into a leading U.S. pharma company which was acquired for $28 billion. Prior to Forest, Mr. Fayad served at Novartis and Schering-Plough in various commercial and strategy roles. After leaving Forest, he worked with a number of smaller biotech and healthcare-oriented companies, including Enumeral Biomedical, where he served as Chairman and CEO, and ACCOY pharmaceuticals, where he co-founded the company and serves on its strategic advisory board.
Mr. Fayad holds a bachelor’s degree in Biology from the American University of Beirut and a Masters of Business Administration degree from Concordia University in Montreal, Canada.
Adrianne Shapira has over 20 years of consumer/retail industry experience across finance and operating roles as well as private and public Board seats. She spent over 13 years at Goldman Sachs as Managing Director in Equity Research leading the Broadlines Retail universe of luxury, department and discount stores, grocers, warehouse clubs and off-price retail. She was the Chief Financial Officer at David Yurman, a privately-held, luxury jewelry brand with a global omni-channel reach. Most recently, she was Managing Director at Eurazeo Brands, a mid-market private equity firm, leading the growth equity financings of over $300 million and serving on the Board of Directors of Beekman 1802, Nest New York, Herschel Supply Company and Dewey’s Cookies. She currently sits on the Board of Directors of Kohl’s Department Stores and previously served as a director of the Hain Celestial Group, Inc., a leading global organic and natural products company.
Ms. Shapira received a B.A. in International Relations from Tufts University and M.B.A. from Columbia Business School.
Adam Borod is a Managing Director at RWN Management, a single-family office based in New York focused primarily on direct investing. Mr. Borod oversees RWN’s Consumer strategy and his primary responsibilities include sourcing, executing, and managing investments within RWN’s private equity portfolio. In addition, Mr. Borod spends time on investment opportunities beyond the Consumer space (excluding real estate) that fit RWN’s mandate. Mr. Borod has direct deal execution experience in early-stage venture, growth equity, middle market leveraged buyouts and real asset transactions.
Prior to RWN, Mr. Borod worked at the Fremont Group, a San Francisco-based private investment firm that manages capital primarily on behalf of one family. At Fremont, Mr. Borod primarily focused on direct investments in the consumer, health and wellness, natural resources, energy tech, and industrial sectors.
Earlier in his career, Mr. Borod worked for Citi’s Technology Investment Banking group and Huron Consulting Group’s Business Advisory division.
Mr. Borod holds a BA from Colgate University and an MBA from the NYU Stern School of Business.
